{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:06:04Z","timestamp":1794258364687,"version":"4.9.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jacl.2026.09.025","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:20:19Z","timestamp":1791123619000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic evidence of an abiraterone\u2013rosuvastatin drug interaction resulting in rhabdomyolysis and acute kidney injury"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0171-0373","authenticated-orcid":false,"given":"Erik","family":"Dove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-6909","authenticated-orcid":false,"given":"Hannah","family":"Lusk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1367-0401","authenticated-orcid":false,"given":"Kara","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jacl.2026.09.025_bib1","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement From the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.025_bib2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00415-019-09185-4","article-title":"A systematic review on the definition of rhabdomyolysis","volume":"267","author":"Stahl","year":"2020","journal-title":"J Neurol"},{"issue":"Pt 5","key":"10.1016\/j.jacl.2026.09.025_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1258\/0004563001899870","article-title":"Biochemical investigation of suspected rhabdomyolysis","volume":"37","author":"Beetham","year":"2000","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.025_bib4","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejim.2006.09.020","article-title":"The syndrome of rhabdomyolysis: pathophysiology and diagnosis","volume":"18","author":"Giannoglou","year":"2007","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.025_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00005792-198205000-00002","article-title":"The spectrum of rhabdomyolysis","volume":"61","author":"Gabow","year":"1982","journal-title":"Med (Baltim)"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.025_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.025_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.clinbiochem.2017.02.016","article-title":"Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management","volume":"50","author":"Cervellin","year":"2017","journal-title":"Clin Biochem"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.025_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.025_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4103\/ijc.IJC_6_21","article-title":"Abiraterone acetate\u2013induced delayed rhabdomyolysis: a rare presentation in metastatic carcinoma prostate","volume":"61","author":"Bahl","year":"2024","journal-title":"Indian J Cancer"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.025_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.nefro.2021.04.014","article-title":"Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin","volume":"43","author":"Cintra","year":"2023","journal-title":"Nefrologia"},{"key":"10.1016\/j.jacl.2026.09.025_bib11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12882-015-0113-6","article-title":"Rhabdomyolysisinduced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report","volume":"16","author":"Neyra","year":"2015","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.025_bib12","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1078155217701294","article-title":"Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: a case report and review of the literature","volume":"24","author":"Dineen","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jacl.2026.09.025_bib13","unstructured":"Ghafouri S, Drakaki A. Abiraterone-induced rhabdomyolysis in prostate cancer: a report of two cases and review of the literature. Ann Clin Case Rep. 2018;3:1533."},{"issue":"2","key":"10.1016\/j.jacl.2026.09.025_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1078155215620921","article-title":"Abiraterone-induced rhabdomyolysis: a case report","volume":"23","author":"Moore","year":"2017","journal-title":"J Oncol Pharm Pract Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.jacl.2026.09.025_bib15","article-title":"Statin-induced rhabdomyolysis due to pharmacokinetic changes from biliary obstruction in a patient with metastatic prostate cancer","volume":"8","author":"Desikan","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.025_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/jcm9010081","article-title":"A cross-sectional study of the relationship between serum creatine kinase and liver biochemistry in patients with rhabdomyolysis","volume":"9","author":"Lim","year":"2019","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.025_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer","volume":"9","author":"Bolek","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.025_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy: a genomewide study","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.09.025_bib19","series-title":"Abiraterone acetate tablets: prescribing information","author":"Apotex Corp","year":"2018"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.025_bib20","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and metaanalysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.025_bib21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cpt.2557","article-title":"The clinical pharmacogenetics implementation consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.jacl.2026.09.025_bib22","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/S0149-2918(03)80316-8","article-title":"Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2026.09.025_bib23","unstructured":"UpToDate. Drug Interactions. Wolters Kluwer. Accessed August 31, 2026. UpToDate Drug Interactions."},{"issue":"4","key":"10.1016\/j.jacl.2026.09.025_bib24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:20:32Z","timestamp":1792236032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"alternative-id":["S1933287426005416"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.025","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic evidence of an abiraterone\u2013rosuvastatin drug interaction resulting in rhabdomyolysis and acute kidney injury","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}